Cardiac amyloidosis includes a group of protein-misfolding diseases characterized by fibril
accumulation within the extracellular space of the myocardium and cardiac dysfunction …

Aims Heart failure with preserved ejection fraction (HFpEF), which is caused by wide various
conditions, has become a major public health problem. Transthyretin amyloid …

Cardio-oncology guidelines, position statements and clinical trials have focused on the
cardiotoxic effects of cancer therapies upon the left ventricle (LV)(1, 2). However, cancer …

Background: Little information is available on the prognostic relevance of cardiac
hemodynamic cutoffs in cardiac amyloidosis (CA) and its subtypes. Methods: Consecutive …

Aims The diagnosis of transthyretin amyloidosis (ATTR) significantly impacts the
management and prognosis of patients initially presenting with heart failure (HF). Despite …

Background This study aims to evaluate the prevalence and the clinical significance of the
right ventricular pulmonary arterial (RV-PA) uncoupling in patients with cardiac amyloidosis …

Aims Predicting mortality in severe AL cardiac amyloidosis is challenging due to elevated
biomarker levels and limited thresholds for stratifying severe cardiac damage. Methods and …

Aims In systemic light-chain (AL) amyloidosis, quantification of right ventricular (RV) amyloid
burden has been limited and the pathogenesis of RV dysfunction is poorly understood …

Aims Our aim was to investigate haemodynamics at rest and during exercise in patients with
transthyretin cardiomyopathy (ATTR‐CM) in light of the 2022 European Society of …

Cardiac amyloidosis (CA) is a progressive infiltrative disease primarily caused by the
accumulation of misfolded, cleaved, and aggregated proteins in the extracellular space of …